OncoMatch/Clinical Trials/NCT05657873
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Is NCT05657873 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Anti-PD-(L)1 based immunotherapy and Platinum based chemotherapy for non small cell lung cancer.
Treatment: Anti-PD-(L)1 based immunotherapy · Platinum based chemotherapy — The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: BRAF wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-(L)1 therapy — first-line metastatic
the planned anti-PD-(L)1-based regimen represents first-line systemic therapy in the metastatic setting
Cannot have received: external beam radiation therapy to the liver
prior external beam radiation therapy to the liver
Lab requirements
Liver function
total bilirubin ≤ 1.5 x uln; ast/ alt ≤ 5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- BAPTIST ALLIANCE - MCI (Data Collection Only) · Miami, Florida
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05657873 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior external beam radiation therapy to the liver disqualifies patients from enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require BRAF?
Yes, BRAF wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages